Clinical Trials

608 enrolled 17 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Phase 2 Active not recruiting

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT04661150 2026-01-30

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

42 enrolled 9 charts

Phase 2 Active not recruiting

Stomach Neoplasms

NCT04721977 2026-01-09

MK-7119-001

66 enrolled 7 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 1 FDA

Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

Phase 1 Completed

62 enrolled 18 charts

Breast Neoplasms

NCT04082364 2025-06-08

MAHOGANY

Phase 2/3 Completed

82 enrolled 22 charts

Stomach Neoplasms

NCT02091960 2025-04-04

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

103 enrolled 17 charts

Breast Neoplasms

NCT00490139 2025-03-21

ALTTO

8,381 enrolled 22 charts

Breast Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT02492711 2025-03-17

SOPHIA

624 enrolled 17 charts 2 FDA

Tumor-Agnostic

Neoplasm Metastasis

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

369 enrolled 19 charts

Breast Neoplasms

NCT01084876 2025-02-11

Compare

475 enrolled 25 charts

Breast Neoplasms

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase 1 Completed

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Phase 1 Completed

18 enrolled 14 charts

Breast Neoplasms

NCT01084863 2025-01-24

Compare

Phase 1/2 Completed

143 enrolled 23 charts

Breast Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Adenocarcinoma Of Esophagus

NCT02675231 2024-11-26

monarcHER

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

117 enrolled 21 charts 1 FDA

Colorectal Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

652 enrolled 15 charts

Breast Neoplasms

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

126 enrolled 16 charts

Breast Neoplasms

NCT02771795 2024-02-02

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Terminated

538 enrolled 9 charts

Breast Neoplasms, Neoplasms

NCT02297698 2023-12-12

HER3+

100 enrolled 11 charts

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

612 enrolled 30 charts 2 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02586025 2023-05-22

PEONY

329 enrolled 33 charts

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast Neoplasms

NCT02419742 2022-10-12

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Phase 4 Completed

110 enrolled 10 charts

BreastGastrointestinalThoracic

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT02162667 2022-08-03

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

562 enrolled 15 charts

HER2-positive Carcinoma of Breast

NCT02154529 2022-04-27

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 1/2 Terminated

17 enrolled 19 charts

CNS

Brain Neoplasms

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

10 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

809 enrolled 14 charts

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

243 enrolled 23 charts

Breast Neoplasms

NCT02536339 2021-12-07

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

40 enrolled 34 charts

Breast Neoplasms

NCT00553358 2021-09-21

Neo ALTTO

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

707 enrolled 20 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT01566721 2021-04-27

SafeHER

2,577 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT01940497 2020-11-03

SCHEARLY

240 enrolled 14 charts